BANB Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.…
Industry Peers
BiotechnologyKey Statistics
About Bachem Holding (SWX: BANB)
›
Bachem Holding (SWX: BANB) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,725 employees.
The shares were at 79.70 CHF on 19 November 2026, up 56.3% over 52 weeks. Its 52-week range is 48.52 CHF to 86.00 CHF: the price is 7.3% below the high and 64.3% above the low.
At a market capitalisation of 5.97B CHF, it trades at 40.3 times trailing earnings and 25.9 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 20% for BANB. It pays a dividend yielding 1.13% (it pays out 45% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Bachem Holding reports return on equity of 10.2%, an operating margin of 21.8% and revenue up 4.3% year over year.
Its debt exceeds its cash by 156.53M CHF, a debt-to-equity ratio of 14.41. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 84.30 CHF is 5.8% above the current price. The next earnings report is expected on 4 March 2027.